PRIMEX-PHARMACEUTICALS
5.10.2016 13:14:48 CEST | Business Wire | Press release
Swiss company Primex Pharmaceuticals AG announces it has submitted a Marketing Authorization Application (MAA) in the EU for ADV6209 to be indicated in children from 6 months to 17 years for moderate sedation before therapeutic or diagnostic procedures, and as premedication prior to anaesthesia.
Primex, working with its partner Advicenne, has submitted the MAA through a decentralized procedure working with the French National Agency for Medicines and Health Products Safety (ANSM) acting as the reference member state on behalf of other concerned member states, including the UK, Italy, Netherlands and Finland.
Mr Alan Knox, Head of Global Marketing comments: “For children, there is a large unmet need for premedication prior to anaesthesia, and a huge unmet need for procedural sedation, such as in emergency and diagnostic procedures”.
Primex acquired the global rights for ADV6209 from the French pharmaceutical laboratory Advicenne SA who had collaborated with Amiens University Hospital.
Kari Sarvanto, President and Co-Founder of Primex Group, adds: “This is an important step for Primex in the area of paediatric anaesthesia, as the annual market potential should be between 100 million euros and 350 million euros.”
Dr Luc-André Granier, CEO of Advicenne, adds: “As one of the very first in-house developed products, this MAA validates our strategy and capabilities in developing original paediatric-adapted drugs.”
About Primex Pharmaceuticals, www.primexpharma.com
Primex Pharmaceuticals is a fast-growing global specialty company spearheading a new lean pharmaceutical business model with the vision to become the leading global innovative anaesthesia pharmaceutical company.
Primex Pharmaceuticals’ global partner network operates in over 40 countries. The company is headquartered in Switzerland. All Primex Pharmaceutical products are manufactured in the EU. Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth (29% CAGR in 2012–2015).
About Advicenne , www.advicenne.com
Advicenne, a specialty pharma, focuses on innovative pediatric medications, targeting orphan or neglected diseases within the fields of neurology and nephrology and aims to become a world leader in those therapeutic areas.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161005005639/en/
Contact:
Primex Pharmaceuticals
Mr Kari Sarvanto, President
Mobile: +41
796 162 694
Email: kari.sarvanto@primexintl.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 15:30:00 CEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 15:30:00 CEST | Press release
Renowned database researcher will lead a new group dedicated to advancing foundational database technology and sharing its work openly with the broader community ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential c
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 15:00:00 CEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 14:30:00 CEST | Press release
BioCatch’s behavioral and device intelligence expertise expected to help detect scams, account takeovers and digital fraud before they happen Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 76
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 14:16:00 CEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom